News
Public · Published
Key facts: China Clears Orforglipron; Hims Deal; Medicare Price Talks
China approved Eli Lilly's oral weight-loss drug orforglipron, the first such filing in the country, while Novo Nordisk's oral Wegovy remained unapproved. Lilly also agreed with Hims & Hers to expand access to approved Zepbound and Foundayo, and said Trulicity and Verzenio entered Medicare price talks.
Published:
Updated:
What happened
China approved Eli Lilly’s oral weight-loss drug orforglipron, the first such filing in the country, while Novo Nordisk’s oral Wegovy remained unapproved. Lilly also agreed with Hims & Hers to expand access to approved Zepbound and Foundayo, and said Trulicity and Verzenio entered Medicare price talks.
Confirmed
Global impact / market context
Orforglipron’s approval gives Lilly an oral option to compete with injectable obesity drugs in China, while the Hims agreement could widen access to two approved medicines without compounded copies. Medicare price negotiations could later change revenue from Trulicity and Verzenio, with new prices scheduled for 2028.
Analyst inference
The update combines potential growth opportunities with pricing pressure for Lilly: broader access and a new oral drug may support sales, while negotiated Medicare prices could reduce revenue on selected medicines. The article provides no sales forecasts, deal financial terms, or market reaction to quantify either effect.
Analyst inference
What to watch
- Watch for details on how orforglipron will be introduced in China and whether its availability develops into meaningful competition with injectable obesity drugs. Analyst inference
- CMS is due to announce negotiated prices for Trulicity and Verzenio by November 30; the new prices are scheduled to take effect in 2028. Confirmed
- Track whether the Hims agreement expands access to Zepbound and Foundayo among eligible patients, while the platform continues to avoid compounded copies of Lilly’s GLP-1 drugs. Analyst inference
Evidence
- Original source link unavailable